Open Questions — ICG-Alone vs Complementary Framing
Resolved
Confirmed by the surgeon (26 Jul 2026): Tc-99m lymphoscintigraphy localised the contralateral (right axilla) node preoperatively, before ICG was used. Dual-tracer (Tc-99m + ICG) is QVH’s routine standard of care — this was not a trial/research protocol testing ICG-alone. ICG’s role was confirmatory/tracing: real-time intraoperative visualisation of the aberrant lymphatic channel itself, running from the left-sided recurrence to the right axillary node.
Resolved framing to use in the Discussion
This is the confirmatory scenario, not independent discovery: “ICG provided anatomical resolution of an aberrant lymphatic channel that dual-tracer localisation alone would have left ambiguous.”
Two consequences for how the paper argues its case:
- Don’t claim this proves ICG-alone would have sufficed — that wasn’t tested here, and a reviewer will ask why Tc-99m was still done if you imply it wasn’t needed. The honest, still-valuable claim is narrower: even within standard dual-modality practice, ICG’s real-time vessel-tracing resolves anatomical detail scintigraphy’s activity map cannot, which matters specifically in aberrant-drainage cases like this one.
- Lean into the actual novel finding instead — the ~20-year latency between the original ipsilateral SLNB and the aberrant contralateral pathway only manifesting at recurrence. Nothing in Theme - Lymphatic Regeneration and Mechanism describes a gap remotely this long; that’s the strongest “why this case is worth publishing” argument (SCARE 6b), stronger than the ICG-alone angle ever was.
Original question (for reference)
Did ICG identify the contralateral node independently of what Tc-99m had already flagged, or did it confirm/trace the path to a node Tc-99m had already localised? → Confirmed: confirmatory. Tc-99m localised the node; ICG traced the aberrant channel to it intraoperatively.